Calcitriol-Mediated Hypercalcemia, Somatostatin Receptors Expression and 25-Hydroxyvitamin D3-1α- Hydroxylase in GIST Tumors

Front Endocrinol (Lausanne). 2022 Jan 26:12:812385. doi: 10.3389/fendo.2021.812385. eCollection 2021.

Abstract

Hypercalcemia is a common complication in cancer patients Mainly caused by Parathyroid hormone-related protein (PTHrP) secretion and metastasis. Calcitriol secretion is a rare source of hypercalcemia in solid tumors, especially in gastrointestinal stromal tumors (GIST). We present a case report of a female patient with a 23 cm gastric GIST that expressed somatostatin-receptors and presented with severe hypercalcemia due to calcitriol secretion. Calcium control was achieved with medical treatment before the use of targeted-directed therapies. Surgery was performed and allowed complete tumor resection. Two years later, patient remains free of disease. Molecular analysis revealed the mRNA expression of 25-hydroxyvitamin D3-1-hydroxylase (1αOHase) and vitamin-D receptors in the tumor cells, confirming the calcitriol-mediated mechanism. Furthermore, the expression of the endotoxin recognition factors CD14 and TLR4 suggests an inflammatory mediated mechanism. Finally, the expression of somatostatin-receptors, especially SST2 might have been related with clinical evolution and prognosis in this patient.

Keywords: GIST tumor; calcitriol; corticoids; hypercalcemia; somatostatin receptors.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Calcifediol
  • Calcitriol / therapeutic use
  • Female
  • Gastrointestinal Stromal Tumors* / drug therapy
  • Humans
  • Hypercalcemia* / genetics
  • Mixed Function Oxygenases
  • Receptors, Somatostatin
  • Vitamin D / analogs & derivatives

Substances

  • Receptors, Somatostatin
  • Vitamin D
  • 25-hydroxyvitamin D
  • Mixed Function Oxygenases
  • Calcitriol
  • Calcifediol